| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Solarase Approved In Canada For Precancerous Skin Lesions MISSISSAUGA, ON -- May 20, 1998 -- The Therapeutic Products Directorate of Health Canada (formerly HPB) has granted marketing approval to Hyal Pharmaceutical Corp.’s Solarase™, a topical gel formulation to treat actinic keratosis (AK), precancerous skin lesions caused by exposure to the sun. AK is a common precancerous skin lesion caused by overexposure to sunlight. A small number of these lesions will develop into squamus cell carcinoma, a malignant skin disease. According to The Skin Cancer Foundation of the United States, AK affects one in six people world-wide. Hyal expects to file a submission to the FDA in the third quarter seeking approval to market Solarase in the U.S. Solarase utilises Hyal's patented HIT technology which targets and retains drugs in areas of dermal pathology. The benefits to the patient are minimal systemic drug absorption and outstanding safety. More information on: Solarase and Hyal Pharmaceutical Corp.
|